

# Supplemental Table 4

	Patients	MVA p-value	MVA Odds Ratio	MVA AUC	
Human Signatures	<b>Clinical* + LumProg-HsEnriched</b>	702 (100%)	0.014	1.50 (1.09-2.09)	0.778
	Clinical* + LumProg-HsEnriched-feature1	702 (100%)	0.030	1.39 (1.04-1.88)	0.777
	<b>Clinical* + MatureLum-HsEnriched</b>	702 (100%)	0.433	0.84 (0.54-1.30)	0.772
	Clinical* + MatureLum-HsEnriched-feature1	702 (100%)	0.523	0.86 (0.53-1.38)	0.772
	<b>Clinical* + Str-MmEnriched</b>	702 (100%)	0.889	1.02 (0.79-1.31)	0.772
	Clinical* + Str-MmEnriched-feature2	702 (100%)	0.198	0.86 (0.69-1.08)	0.773
	Clinical* + Str-MmEnriched-feature3	702 (100%)	0.048	0.79 (0.62-1.00)	0.776
	Clinical* + Str-MmEnriched-feature4	702 (100%)	0.389	0.91 (0.72-1.13)	0.771
	<b>Clinical* + fMaSC-MmEnriched</b>	702 (100%)	0.216	1.14 (0.93-1.39)	0.773
	Clinical* + fMaSC-MmEnriched-feature1	702 (100%)	0.013	1.48 (1.09-2.03)	0.777
Clinical* + fMaSC-MmEnriched-feature2	702 (100%)	0.031	0.71 (0.52-0.97)	0.777	
Mouse Signatures	<b>aMaSC-MmEnriched</b>				
	Clinical* + aMaSC-MmEnriched-feature1	702 (100%)	0.749	1.04 (0.82-1.32)	0.772
	Clinical* + aMaSC-MmEnriched-feature3	702 (100%)	0.018	0.77 (0.61-0.95)	0.775
	<b>LumProg-MmEnriched</b>				
	Clinical* + LumProg-MmEnriched-feature2	702 (100%)	0.805	0.96 (0.70-1.33)	0.772
	<b>MatureLum-MmEnriched</b>				
	Clinical* + MatureLum-MmEnriched-feature1	702 (100%)	0.697	0.95 (0.73-1.24)	0.772
	Clinical* + MatureLum-MmEnriched-feature2	702 (100%)	0.671	1.06 (0.82-1.37)	0.772
	Clinical* + MatureLum-MmEnriched-feature3	702 (100%)	0.128	1.38 (0.91-2.11)	0.773
	Clinical* + MatureLum-MmEnriched-feature4	702 (100%)	0.461	1.09 (0.87-1.37)	0.772
	Clinical* + MatureLum-MmEnriched-feature7	702 (100%)	0.577	1.07 (0.85-1.34)	0.772
	Clinical* + MatureLum-MmEnriched-feature8	702 (100%)	0.388	0.85 (0.58-1.24)	0.772
	Published Signatures	<b>Usary et al (PMID:23780888)</b>			
Clinical* + Usary Untreated Hum		702 (100%)	0.001	1.90 (1.29-2.83)	0.777
Clinical* + Usary Resp Hum		702 (100%)	0.021	1.35 (1.05-1.74)	0.774
<b>Hatzi et al (PMID:21558518)</b>					
Clinical* + Chemosensitive					
Insensitive		315 (44.9%)		1	0.817
Sensitive		151 (21.5%)	<0.001	4.38 (2.50-7.84)	
Not available		236 (33.6%)			
Clinical* + Chemoresistance					
RCB_0_I		211 (30.1%)		1	0.860
RCB_II_III	255 (36.3%)	<0.001	0.11 (0.06-0.21)		
Not available	236 (33.6%)				

\*Clinical variables consist of Age, ER, PR, HER2, Tumor Stage, PAM50 Subtype, and PAM50 Proliferation Score